AstraZeneca stock gains after Deutsche Bank upgrade and lung cancer trial success

Published on 09/20/2026 at 14:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock trades at GBP 125.00 as of September 18, 2026, about 20 percent below the GBP 150.00 analyst consensus target. Deutsche Bank lifted its target to 11,700 pence on September 15, 2026 after a key SERENA-4 lung cancer readout shifted the risk-reward profile.

Wissenschaftler im weißen Kittel arbeiten in modernem Pharma-Forschungslabor — AstraZeneca plc (ISIN GB0009895292) betreibt moderne Forschungslabore für pharmazeutische Wirkstoffentwicklung und klinische Studien weltweit, Illustration mit AI erstellt.

AstraZeneca PLC stock (ISIN GB0009895292) is trading around GBP 125.00 on the London Stock Exchange as of September 18, 2026, while analysts now see upside to GBP 150.00 and Deutsche Bank has nudged its price target to 11,700 pence after a pivotal lung cancer study update.

Analyst upgrades follow SERENA-4 lung cancer data

According to Sharecast on September 15, 2026, Deutsche Bank upgraded AstraZeneca from sell to hold and raised its target price from 11,500 pence to 11,700 pence, citing a changed risk-reward profile after last week's negative SERENA-4 readout and a period of underperformance versus European large-cap peers.

The new 11,700 pence target implies modest upside of about 1.6 percent from the September 18, 2026 closing level of 12,500 pence reported by Investing.com, but Deutsche Bank's stance marks a clear softening compared with its earlier sell recommendation.

Stock trades below 52-week high despite pipeline progress

As of September 18, 2026, AstraZeneca closed at 12,500.0 pence in London, up 72.0 pence or 0.58 percent on the day, with an intraday range between 12,398.0 and 12,596.0 pence and trading volume of 6.52 million shares, according to data from Investing.com.

Per MarketBeat on September 19, 2026, AstraZeneca's 52-week range spans from GBP 107.84 to GBP 157.32, so the current price around GBP 125.00 leaves the stock roughly GBP 32.32 or about 20.5 percent below the 52-week high.

MarketBeat also reports that AstraZeneca's market capitalization stands at about GBP 193.86 billion as of September 19, 2026 and that the shares have fallen 9.4 percent year to date from GBP 137.90 at the start of 2026 to GBP 125.00, underscoring the underperformance Deutsche Bank highlighted in its rating change.

Latest fundamentals and valuation backdrop

According to MarketBeat, AstraZeneca currently generates annual sales of about GBP 61.37 billion and net income of GBP 8.71 billion, translating into a net margin of 17.02 percent based on its most recently reported full-year figures within the last 24 months.

On these numbers, the stock trades at a trailing price-to-earnings ratio of 18.71 and a price-to-sales ratio of 3.16, while the price-to-book ratio of 4.75 reflects the premium investors are willing to pay for AstraZeneca's portfolio of oncology, cardiovascular, renal and respiratory medicines, as summarized by MarketBeat.

The company pays a dividend with a yield of 1.92 percent and a payout ratio of 47.41 percent, a level that MarketBeat describes as sustainable, giving income-oriented shareholders some return even as the stock trades below its recent highs.

Consensus targets and insider confidence

Based on the consensus reported by MarketBeat, AstraZeneca carries a Moderate Buy rating, with six buy recommendations and one hold and no sell ratings, and an average price target of GBP 150.00, implying about 20.0 percent upside from the current GBP 125.00 share price.

The valuation also looks supported by a price-to-earnings-growth (PEG) ratio of 0.86, according to MarketBeat, a level below 1 that often signals that forecast earnings growth is not fully reflected in the share price.

Insider buying adds to the picture: MarketBeat notes that insiders have acquired about GBP 303,025 worth of AstraZeneca stock over the last three months while not selling any shares, indicating management confidence in the long-term prospects of the business.

Risk factors investors are watching

Deutsche Bank's reference to the negative SERENA-4 lung cancer readout shows that clinical trial outcomes remain a key risk for AstraZeneca: setbacks in late-stage oncology studies can weigh on sentiment and pipeline valuations, as highlighted in the broker's commentary reported by Sharecast.

At the same time, MarketBeat's data show that AstraZeneca operates with a debt-to-equity ratio of 64.10 and a current ratio of 0.89, which means leverage and liquidity remain important metrics for investors to monitor alongside the pipeline news flow and regulatory decisions in key markets.

Stock price context for AstraZeneca

In London, AstraZeneca stock closed at 12,500.0 pence on September 18, 2026, on the primary London Stock Exchange listing, which serves as the reference price for investors assessing the shares' performance and distance to the 52-week high of GBP 157.32 in the current trading environment.